Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SatisfACtion trial of actinium-225 PSMA-R2 in metastatic prostate cancer
2023-507672-52-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Jan 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of actinium-225 PSMA-R2 in prostate cancer (PCa) and metastatic castration-resistant prostate cancer (mCRPC) (5 arms), sponsored by Novartis. Primary endpoints: Safety, Overall response rate and 1 more. Planned start Jan 2024; status: authorised.
02
Drugs
actinium-225 PSMA-R2
03
Conditions
prostate cancer (PCa)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2023-507672-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507672-52-00.